These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21852390)

  • 1. Denosumab for bone diseases: translating bone biology into targeted therapy.
    Tsourdi E; Rachner TD; Rauner M; Hamann C; Hofbauer LC
    Eur J Endocrinol; 2011 Dec; 165(6):833-40. PubMed ID: 21852390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal and extraskeletal actions of denosumab.
    Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
    Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
    Sugimoto T
    Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
    Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
    J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
    Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
    Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
    Body JJ; Lipton A; Gralow J; Steger GG; Gao G; Yeh H; Fizazi K
    J Bone Miner Res; 2010 Mar; 25(3):440-6. PubMed ID: 19653815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging treatments for postmenopausal osteoporosis - focus on denosumab.
    Geusens P
    Clin Interv Aging; 2009; 4():241-50. PubMed ID: 19554095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab: an update.
    Bogado CE; Boailchuk JA; Zanchetta MB; Massari FE; Zanchetta JR
    Drugs Today (Barc); 2011 Aug; 47(8):605-13. PubMed ID: 21850283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
    Maldonado-Gonzales E; Pietschmann P
    Wien Med Wochenschr; 2010 Sep; 160(17-18):458-63. PubMed ID: 20714812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK ligand inhibition with denosumab for the management of osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [RANKL inhibition as therapy for joint damage].
    Akama H
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Oct; 30(5):404-7. PubMed ID: 17984581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RANKL-RANK Axis: A Bone to Thymus Round Trip.
    Sobacchi C; Menale C; Villa A
    Front Immunol; 2019; 10():629. PubMed ID: 30984193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
    Hofbauer LC; Schoppet M
    JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.